Group items tagged

Wegovy maker Novo Nordisk said on Tuesday (Aug 8) a large study had shown the highly effective obesity treatment also had a clear cardiovascular benefit, boosting the Danish company's hopes of moving beyond its image as a lifestyle drug. The increasingly popular Wegovy has transformed the weight-loss market since its U.S. launch in June 2021, capturing the attention of patients, investors and celebrities worldwide. Novo's news lifted shares in Europe's second-most valuable listed company after LVMH by more than 17 per cent to record highs. They have now surged almost 165 per cent over the past two years. The results of the late-stage trial may help persuade insurers in the U.S. and cost-conscious health authorities in Europe to cover the cost of Wegovy, which is $1,300 a month in the United States, for a wider range of patients. U.S. law classifies weight-loss treatments as lifestyle drugs and bars the Medicare health plan for older Americans from covering them and experts said the new data could lead the U.S. government to reassess that.

Weight loss drug Wegovy has transformed the obesity market and pharmaceutical companies with existing treatments are hoping the resulting demand will boost demand for their older, less effective but cheaper, drugs. A weekly injection of Wegovy, which was launched in the U.S. in June 2021, leads to an average weight loss of around 15%, alongside changes to diet and exercise. Its impact has captured the attention of patients, investors and even celebrities. But supply issues for Wegovy manufacturer Novo Nordisk means the Danish drugmaker has struggled to meet surging U.S. demand, delaying a launch in most of Europe. Insurers and some national governments have also baulked at its cost, while a minority of patients do not respond to it. Vivus and Currax Pharmaceuticals, U.S.-based developers whose treatments have been on the U.S. market for around a decade, hope to benefit from the attention and supply shortage. But scientists and investors say that lower efficacy plus side effects could continue to hold the treatments back.

S-Ergo 106 is a lightweight wheelchair with angle adjustable backrest and equipped with the unique patented S-Ergo seating system .S-Ergo system provides pressure relief and helps to prevent the user sliding down the seat.S-Ergo 106 also has stylish oval-shaped tubes, which creates more streamlined appearance and enhances the strength of the structure. Features- Fixed armrests Fixed footrests High strength frame Lightweight (27 lbs.) Anti-bacterial, removable/washable upholstery Folding precision backrest "Tube-in-center" footplate assures side leg support 24" Rear polyurethane, high-profile flat-free wheels Rear anti-tippers

The U.S. durable medical equipment market size was valued at USD 52.9 billion in 2020. It is expected to expand at a compound annual growth rate (CAGR) of 6.0% over the forecast period.

Pandemic influenza wave that severely affected the U.S.A. cause viral infection in many people, this in an earlier period than traditionally high incidence in this country in late January and early February. As we know, the flu symptoms 2013 cause several deaths in the U.S. and spread to almost the entire country. Flu symptoms 2013 are quite severe and lead to some dangerous complications. That is why the body after ill health can be restored to the maximum, because, unfortunately, suffered from the new flu virus does not provide immunity against seasonal flu, nor other types of common viral infections.

ovial accounts of a jubilant drink: Coffee is not bad if done within limits. In fact, there are many who will be absolutely shocked on putting this crisis buster under such gruesome lights. So you may well imagine what it means to them putting on those really heavy stigmas; however, lighten up before we make our Cup of Joe (it's 'JOE'; not joy as many think it to be) appear for the court martial; discussing the secrets behind this human name will lighten things up to several degrees. At least, that's what coffee did to the U.S. Navy crews when alcohol was banned aboard in 1914 and the idea of the U.S. Navy secretary - Joe Daniels - clung on big time. His name, thus, has ever since been immortalized and perhaps envied big time by the Turkish soul who left behind the beans while retreating from Austria. He now has a pal, too; the Viennese guy who, out of compulsion, added plenteous milk and sugar to the brew and made the world's first cappuccino, named to show the friar from the Capuchin order of monks the due respects for his bravery against the Turks. But all that is history and we are dealing with the present.

Dr. Michael Omidi MD, along with his brother Julian Omidi, is cofounder of No More Poverty, an organization promoting the works of charities that strive to end poverty and the conditions that cause poverty both in the U. S. and abroad. In this article, Dr. Michael Omidi discusses the Omidi brothers' sponsorship of Jessica's Hope Project, a foundation that sends healthy care packages to U.S. soldiers overseas.

Few if any industries are growing at a quicker and more consistent pace in the U.S. than marijuana. A report released earlier this year by Marijuana Business Daily entitled "Marijuana Business Factbook 2017" found that the U.S. legal-weed market is expected to grow by 45% in 2018, and an aggregate of 300% between 2016 and 2021. If these projections are accurate, we could be talking about a $17 billion market by 2021. With growth like this, it's no wonder why marijuana stocks have gone through the roof in recent years.

The U.S. wound care centers market size is expected to reach USD 18.1 billion by 2028, according to a new report

The U.S. infections imaging market size was valued at USD 29.72 billion in 2021 and is expected to expand at a compound annual growth rate (CAGR) of 4.3% from 2022 to 2030

Japanese pharmaceutical firm Eisai Co plans to seek full approval of its experimental Alzheimer's drug lecanemab in the United States, Europe and Japan armed with data showing it can slow the brain-wasting disease for people with early symptoms, potentially getting the treatment to patients next year. It remains unclear how widely the drug developed with U.S. biotech Biogen Inc will be used due to uncertainty over insurance coverage, including the U.S. government's Medicare plan for people age 65 and over, potential side effects and cost. One Wall Street analyst told Reuters news agency that he is not counting on measurable sales until 2024. Several estimated lecanemab may be priced at around $20,000 per year. "Most people who this (drug) would apply to are on Medicare, and most private payers look to Medicare as they make their own (coverage) decisions. So there's a massive roadblock in the way of all who could benefit from this treatment," said Robert Egge, Alzheimer's Association chief public policy officer. Eisai confirmed on Tuesday (November 30) that lecanemab - an antibody designed to remove sticky deposits of a protein called amyloid beta from the brain - reduced the rate of cognitive decline on a clinical dementia scale by 27% compared to a placebo. It also gave new details on side effects including a dangerous type of brain swelling and brain bleeding.

The first big breakthrough in 30 years of Alzheimer's research is providing momentum for clinical trials of "cocktail" treatments targeting the two hallmark proteins associated with the mind-robbing disease, according to interviews with researchers and pharmaceutical executives. Drugmakers Eisai and Biogen reported in September that their therapy lecanemab could slow progress of the disease by 27% over 18 months compared with a placebo. The finding validates the theory that clearing the amyloid protein that forms clumps in the brains of Alzheimer's patients could slow or halt the disease and has strengthened the support from some scientists for simultaneously targeting another notorious protein linked to Alzheimer's: tau. Eisai and Biogen are scheduled to present full data from their lecanemab study on Tuesday at the Clinical Trials on Alzheimer's Disease conference in San Francisco. The U.S. Food and Drug Administration is expected to make a decision by early January on the companies' application for accelerated approval. If approved on an accelerated basis, the companies said they would immediately apply for full U.S. regulatory approval which could help secure Medicare coverage.

Online retail giant Amazon said on Tuesday (January 24) it is offering a $5 monthly subscription plan for U.S. Prime members that will cover a range of generic drugs and their doorstep delivery, furthering the ecommerce giant's push into healthcare. The program, named RxPass, includes more than 50 medications addressing over 80 chronic conditions such as high blood pressure, anxiety, diabetes and male pattern baldness, Vin Gupta, Amazon Pharmacy's chief medical officer, has said. However, customers enrolled in Medicare, Medicaid or any other government healthcare program will not be able to enrol in Amazon Pharmacy's RxPass service. The average Prime member would save about $100 per year with RxPass, John Love, vice president of Amazon Pharmacy, said. Amazon Prime members in most U.S. states can sign up for the program from January 24. The flat $5 charge would be without insurance and on top of the Prime membership fee, which costs $139 per year in the United States.

MedsDelta provides Sunitinib Capsules by Pfizer makes under trade name Sutent capsules, availing at a reasonable price. Sunitinib is for treating a specific sort of stomach, gut, or throat tumor in specific patients. It is additionally used to treat certain sorts of kidney or pancreatic tumor. #MedsDelta exporting Generic Sunitinib Capsules across all over the world, countries like U.K., U.S, Nepal, Philippines, China, Japan, Singapore, Romania, Vietnam, Canada, Hongkong, Russia, and over 150 countries. We at MedsDelta, supplying Generic #Sunitinib Medicines at reasonable prices and giving you accurate information about the product. If you want to order Generic Sunitinib Capsules - #Sutent25mg Capsules, you can contact us anytime 24*7 at -> +91-9971646666, QQ: 3451266709, Skype: medsdelta, WeChat: medsdelta, or mail: medsdelta@gmail.com. We ensure to provide our best services and authentic medication.